Investigating how a mitochondrial protein affects pancreatic cancer spread and gene regulation
Defining the role of the mitochondrial protein, GOT2, in pancreatic cancer metastasis and epigenetic dysregulation
['FUNDING_FELLOWSHIP'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-10999039
This study is looking at how a protein called GOT2 affects the spread of pancreatic cancer and how it might change the way cancer cells behave, which could help us find better treatments for patients.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-10999039 on ClinicalTrials.gov |
What this research studies
This research focuses on pancreatic adenocarcinoma, a highly aggressive cancer with a poor prognosis. The team is exploring the role of the mitochondrial protein GOT2 in the metastasis of this cancer and its potential impact on epigenetic changes. Using mouse models, they aim to understand how GOT2 influences tumor development and the immune environment, which could lead to new insights into treatment strategies. Patients may benefit from findings that could improve understanding of cancer progression and treatment resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic adenocarcinoma, particularly those with advanced stages of the disease.
Not a fit: Patients with early-stage pancreatic cancer or those with other types of cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets for pancreatic cancer, potentially improving patient outcomes.
How similar studies have performed: Previous studies have shown promising results in understanding the role of mitochondrial proteins in cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DIAZ, LUIS FRANCISCO — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: DIAZ, LUIS FRANCISCO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.